Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Leptomeningeal Carcinomatosis Clear all
Completed Phase 1 Interventional

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

NCT03719768
View directory record Official record
Conditions
Leptomeningeal Metastases, Leptomeningeal Disease
Interventions
Avelumab, Whole Brain Radiotherapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases

NCT03520504
View directory record Official record
Conditions
Leptomeningeal Metastases
Interventions
Proton craniospinal irradiation (CSI)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Jul 21, 2026, 3:59 PM EDT
Recruiting Phase 3 Interventional

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT06500481
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Involved-Field Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Quality-of-Life Assessment
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
58
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Encinitas, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Terminated Phase 2 Interventional

Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors

NCT02684071
View directory record Official record
Conditions
Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Abundant Neuropil and True Rosettes, Metastatic Malignant Neoplasm to the Leptomeninges
Interventions
Intra thecal methotrexate, topotecan, cyclophosphamide
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
Up to 22 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors

NCT00003462
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
busulfan
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jul 21, 2026, 3:59 PM EDT
Terminated Phase 1 Interventional

Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine

NCT00074607
View directory record Official record
Conditions
Meningitis, Neoplasms
Interventions
Gemcitabine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
5
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2012 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Melphalan in Patients With Neoplastic Meningitis

NCT00002750
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Leukemia, Lymphoma, Ovarian Cancer
Interventions
melphalan
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Phase 1 Intrathecal Topotecan for Neoplastic Meningitis

NCT00674674
View directory record Official record
Conditions
Neoplastic Meningitis
Interventions
Topotecan
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Jul 21, 2026, 3:59 PM EDT
Active, not recruiting Phase 1 Interventional

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

NCT04661384
View directory record Official record
Conditions
Ependymoma, Glioblastoma, Medulloblastoma, Recurrent Metastatic Malignant Neoplasm in the Leptomeninges
Interventions
IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 2 Interventional

Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors

NCT04343573
View directory record Official record
Conditions
Leptomeningeal Metastases
Interventions
Involved-field Photon Radiation Therapy, Proton Craniospinal Irradiation (CSI), Neurocognitive Assessment, MDASI-BT and MDASI-SP
Radiation · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

NCT02228369
View directory record Official record
Conditions
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Interventions
AZD3759, AZD9291
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Safety Study of Afatinib for Brain Cancer

NCT02423525
View directory record Official record
Conditions
Brain Cancer
Interventions
Afatinib
Drug
Lead sponsor
Santosh Kesari
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Jul 21, 2026, 3:59 PM EDT
Not yet recruiting Not applicable Interventional

Wearable-Triggered Digital Safety Net for Real-Time Monitoring & Intervention in Leptomeningeal Metastasis

NCT07704034
View directory record Official record
Conditions
Leptomeningeal Metastasis
Interventions
Calibration Phase, Stepped Wedge Intervention Phase
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Completed No phase listed Interventional Results available

Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer

NCT02948751
View directory record Official record
Conditions
Breast Cancer, Leptomeningeal Metastasis
Interventions
OncoCEE
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors

NCT00031928
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
mafosfamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
9
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jul 21, 2026, 3:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

NCT04588545
View directory record Official record
Conditions
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
Interventions
Radiation Therapy, Pertuzumab, Trastuzumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Completed No phase listed Observational

Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)

NCT02071056
View directory record Official record
Conditions
Leptomeningeal Metastasis
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Jul 21, 2026, 3:59 PM EDT
Withdrawn Phase 1Phase 2 Interventional

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

NCT04315246
View directory record Official record
Conditions
Leptomeningeal Metastasis, Solid Tumor, Adult
Interventions
radiolabeled DPTA-omburtamab
Biological
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Jul 21, 2026, 3:59 PM EDT
Terminated Phase 1 Interventional

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

NCT00515788
View directory record Official record
Conditions
Neoplastic Meningitis
Interventions
DepoCyt, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2012 · Synced Jul 21, 2026, 3:59 PM EDT
Recruiting Not applicable Interventional

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

NCT05746325
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Metastatic Lung Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Digital Photography, Lumbar Puncture, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Biospecimen Collection
Other · Procedure · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Terminated Not applicable Interventional Results available

Depocyt® With Sorafenib in Neoplastic Meningitis

NCT00964743
View directory record Official record
Conditions
Neoplastic Meningitis
Interventions
DepoCyt, Sorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Jul 21, 2026, 3:59 PM EDT
Terminated Phase 1 Interventional

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

NCT03661424
View directory record Official record
Conditions
Breast Cancer Female, Leptomeningeal Metastases
Interventions
HER2 BATs
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Jul 21, 2026, 3:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

NCT01596127
View directory record Official record
Conditions
Leukemia, Lymphoid Malignancies, Metastatic Malignant Neoplasm to the Leptomeninges
Interventions
Intrathecal Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer

NCT00992602
View directory record Official record
Conditions
Central Nervous System Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer, Stage IV Breast Cancer, Tumors Metastatic to Brain
Interventions
methotrexate, liposomal cytarabine, quality-of-life assessment, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Jul 21, 2026, 3:59 PM EDT